Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
作者： L Crinò , G Scagliotti , M Marangolo , F Figoli , M Clerici
DOI: 10.1200/JCO.1997.15.1.297
关键词:
摘要: PURPOSEThe nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin preclinical models suggested synergy between two drugs. The aim study was to evaluate clinical efficacy and toxicity cisplatin-gemcitabine advanced NSCLC.PATIENTS AND METHODSForty-eight consecutive previously untreated NSCLC patients entered trial from January June 1994. median age 60 years (range, 37 70) performance status (PS) 0 or 1; 22 had unresectable stage III disease (21 IIIB one IIIA) 26 IV disease. Gemcitabine 1 g/m2 administered weekly (days 1, 8, 15) followed by 1-week rest 100 mg/m2 on day 2 each 28-day cycle. Survival response were determined accordance intention-to-treat principle all enrolled patients.RESULTSOf 48 assessable patients, (stage IV) complete res...
elsevier.com
researchgate.net 
sci-hub.se 参考文章(18)
Larry W. Hertel, Peng Huang, William Plunkett, Gerald B. Grindey, Sherri Chubb, Sherri Chubb, Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Research. ,vol. 51, pp. 6110- 6117 ,(1991)
R P Abratt, W R Bezwoda, G Falkson, L Goedhals, D Hacking, T A Rugg, Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 12, pp. 1535- 1540 ,(1994) , 10.1200/JCO.1994.12.8.1535
H Anderson, B Lund, F Bach, N Thatcher, J Walling, H H Hansen, Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 12, pp. 1821- 1826 ,(1994) , 10.1200/JCO.1994.12.9.1821
Alastair J.J. Wood, Daniel C. Ihde, Chemotherapy of Lung Cancer The New England Journal of Medicine. ,vol. 327, pp. 1434- 1441 ,(1992) , 10.1056/NEJM199211123272006
Lucio Crino, Maurizio Tonato, Samir Darwish, Maria L. Meacci, Enrichetta Corgna, Francesco Di Costanzo, Franco Buzzi, Giovanni Fornari, Emilio Santi, Enzo Ballatori, Carla Santucci, Stephen Davis, A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group Cancer Chemotherapy and Pharmacology. ,vol. 26, pp. 52- 56 ,(1990) , 10.1007/BF02940294
A. Sandler, R. Ansari, J. McClean, W. Fisher, F.A. Dorr, L.H. Einhorn, 1079 Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study European Journal of Cancer. ,vol. 31, pp. S225- ,(1995) , 10.1016/0959-8049(95)96325-8
James L. Abbruzzese, Philip Frost, Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin. Cancer Chemotherapy and Pharmacology. ,vol. 30, pp. 31- 36 ,(1992) , 10.1007/BF00686482
G C Todd, L W Hertel, G B Boder, G A Poore, J S Kroin, G B Grindey, S M Rinzel, Evaluation of the Antitumor Activity of Gemcitabine (2′,2′-Difluoro-2′-deoxycytidine) Cancer Research. ,vol. 50, pp. 4417- 4422 ,(1990)
Godefridus J. Peters, Catharina M. Kuiper, Gijsbert Veerman, Andries M. Bergman, Ruiz van Haperen, Synergistic interaction between cisplatin and gemcitabine in vitro. Clinical Cancer Research. ,vol. 2, pp. 521- 530 ,(1996)
Larry W. Hertel, Theodore S. Lawrence, Emily Chang, Donna S. Shewach, Tina M. Hahn, Metabolism of 2′,2′-Difluoro-2′-Deoxycytidine and Radiation Sensitization of Human Colon Carcinoma Cells Cancer Research. ,vol. 54, pp. 3218- 3223 ,(1994)